Founded in 2004, Rundo Pharmaceutical R&D (Shanghai) Co., Ltd. is a contract research organization (CRO) providing a one-stop shop for the provision of clinical trial management services. It was the first CRO in China having obtained ISO 9001:2008 and CRO Industry Standard certification. Rundo also founded the China CRO Union (CROU) and continues to be its main advocate, holding the presidency of the organization along with the presidency of the CRO Branch of the China Pharmaceutical Quality Management Association. The company is headquartered in Shanghai, with a branch in Beijing and offices/staff stationed in 60 cities across China, including Guangzhou and Hangzhou. Rundo also has five subsidiaries -Nantong Rundo Pharmaceutical R&D Co., Ltd.(statistical analysis); Primium Site Management Co., Ltd. (largely focused on the SMO business); Shanghai Rundo Med-Tech Co., Ltd. (Phase | clinical trial management); a Japanese subsidiary and a U.S. subsidiary, the latter two having been set up to provide services for Chinese pharmaceutical companies going abroad and for overseas pharmaceutical companies wishing to enter the Chinese market. Since its establishment, Rundo has been adhering to the concepts of integrity-based pursuit of excellence and has always viewed the conduct of high-quality clinical trials that meet exacting standards as its lifeblood with more than1500 Phase I to Phase IV clinical trial projects having been successfully completed across a range of therapeutic fields including oncology, cardiovascular, respiratory, digestive, endocrine, neurological and anti-infection, among others. The company has come to be trusted by clients, praised by investigators, and recognized by the industry at large. As one of the leading CRO companies in China, Rundo has a professional and dedicated team with rich experience in clinical studies, providing a one-stop shop for the conduct of high-quality and efficient clinical studies that comply with theICH-GCP standards and NMPA regulations. The company has also seen its business expand beyond China, firstly to the Asia-Pacific region followed by expansion into the European and American.